Masatora Yamasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masatora Yamasaki has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Keiichiro Matsumoto
Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga, Japan
1 shared publication - Makoto Fukuda
Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan
1 shared publication - Motoaki Miyazono
Department of Nephrology Faculty of Medicine Saga University Saga Japan
1 shared publication - Tsuyoshi Takashima
Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga, Japan
1 shared publication - Yasunori Nonaka
Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga, Japan
1 shared publication - Yuji Ikeda
Department of Internal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga, Japan
1 shared publication
Latest Publications
- Open Access
- 6 July 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 221
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with refractory nephrotic syndrome. A 61-year-old woman was diagnosed with minimal change-type nephrotic syndrome in October 2012. She received prednisolone (PSL) and cyclosporin A (CyA), but she experienced several cycles of relapse and remission and was hospitalized in May 2016 due to relapse. However, in spite of steroid pulse therapy and adrenocorticotropic hormone (ACTH) administration, her urinary protein level did not improve. We started her on evolocumab with the expectation of equivalent LDL-lowering effects as seen with LDL apheresis. After that, the LDL cholesterol level and UP/UC were concomitantly decreased, and the serum albumin was increased. This was maintained even when we reduced the PSL dose. This suggests that evolocumab clinically improves the nephrotic condition. No other report has described the use of evolocumab for nephrotic syndrome (NS) or its effect on similar nephrotic conditions. We believe that the findings presented here are unique and may be beneficial when treating similar cases.
- 6 July 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 221
Open AccessSuccessful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with refractory nephrotic syndrome. A 61-year-old woman was diagnosed with minimal change-type nephrotic syndrome in October 2012. She received prednisolone (PSL) and cyclosporin A (CyA), but she experienced several cycles of relapse and remission and was hospitalized in May 2016 due to relapse. However, in spite of steroid pulse therapy and adrenocorticotropic hormone (ACTH) administration, her urinary protein level did not improve. We started her on evolocumab with the expectation of equivalent LDL-lowering effects as seen with LDL apheresis. After that, the LDL cholesterol level and UP/UC were concomitantly decreased, and the serum albumin was increased. This was maintained even when we reduced the PSL dose. This suggests that evolocumab clinically improves the nephrotic condition. No other report has described the use of evolocumab for nephrotic syndrome (NS) or its effect on similar nephrotic conditions. We believe that the findings presented here are unique and may be beneficial when treating similar cases.